NCT03431909View on ClinicalTrials.gov

Evaluation Of HUK in Acute Stroke Patients: MRS and CTP

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 1, 2014

Primary Completion Date

October 1, 2016

Study Completion Date

October 1, 2016

Conditions
Acute Ischemic Stroke
Interventions
DRUG

Human urinary kallidinogenase (HUK)

Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)

DRUG

aspirin® , clopidogrel® , atorvastatin®

Patients in control group will receive foundation treatment, including aspirin® (100 mg/d), clopidogrel® (75 mg/d), and atorvastatin® (20 mg/d) for 14 days

All Listed Sponsors
lead

Xuanwu Hospital, Beijing

OTHER

NCT03431909 - Evaluation Of HUK in Acute Stroke Patients: MRS and CTP | Biotech Hunter | Biotech Hunter